Checkpoint Therapeutics (CKPT) Competitors $4.03 -0.03 (-0.74%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$4.04 +0.00 (+0.12%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CKPT vs. QURE, ABCL, CMRX, PRAX, LENZ, BCAX, CRON, PRTA, AVBP, and ORGOShould you be buying Checkpoint Therapeutics stock or one of its competitors? The main competitors of Checkpoint Therapeutics include uniQure (QURE), AbCellera Biologics (ABCL), Chimerix (CMRX), Praxis Precision Medicines (PRAX), LENZ Therapeutics (LENZ), Bicara Therapeutics (BCAX), Cronos Group (CRON), Prothena (PRTA), ArriVent BioPharma (AVBP), and Organogenesis (ORGO). These companies are all part of the "pharmaceutical products" industry. Checkpoint Therapeutics vs. uniQure AbCellera Biologics Chimerix Praxis Precision Medicines LENZ Therapeutics Bicara Therapeutics Cronos Group Prothena ArriVent BioPharma Organogenesis Checkpoint Therapeutics (NASDAQ:CKPT) and uniQure (NASDAQ:QURE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, community ranking, media sentiment, valuation, dividends, profitability, risk and analyst recommendations. Which has higher valuation and earnings, CKPT or QURE? Checkpoint Therapeutics has higher earnings, but lower revenue than uniQure. uniQure is trading at a lower price-to-earnings ratio than Checkpoint Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCheckpoint Therapeutics$47K4,187.17-$51.85M-$1.84-2.19uniQure$27.12M26.18-$308.48M-$4.93-2.66 Does the MarketBeat Community believe in CKPT or QURE? uniQure received 475 more outperform votes than Checkpoint Therapeutics when rated by MarketBeat users. Likewise, 70.54% of users gave uniQure an outperform vote while only 67.04% of users gave Checkpoint Therapeutics an outperform vote. CompanyUnderperformOutperformCheckpoint TherapeuticsOutperform Votes18167.04% Underperform Votes8932.96% uniQureOutperform Votes65670.54% Underperform Votes27429.46% Is CKPT or QURE more profitable? Checkpoint Therapeutics has a net margin of 0.00% compared to uniQure's net margin of -837.80%. Checkpoint Therapeutics' return on equity of 0.00% beat uniQure's return on equity.Company Net Margins Return on Equity Return on Assets Checkpoint TherapeuticsN/A N/A -659.07% uniQure -837.80%-188.82%-32.17% Do institutionals & insiders believe in CKPT or QURE? 22.0% of Checkpoint Therapeutics shares are held by institutional investors. Comparatively, 78.8% of uniQure shares are held by institutional investors. 2.1% of Checkpoint Therapeutics shares are held by company insiders. Comparatively, 4.7% of uniQure shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts recommend CKPT or QURE? Checkpoint Therapeutics presently has a consensus target price of $4.33, suggesting a potential upside of 7.53%. uniQure has a consensus target price of $38.89, suggesting a potential upside of 196.18%. Given uniQure's stronger consensus rating and higher probable upside, analysts plainly believe uniQure is more favorable than Checkpoint Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Checkpoint Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33uniQure 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.80 Does the media refer more to CKPT or QURE? In the previous week, Checkpoint Therapeutics and Checkpoint Therapeutics both had 2 articles in the media. Checkpoint Therapeutics' average media sentiment score of 0.96 beat uniQure's score of 0.93 indicating that Checkpoint Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Checkpoint Therapeutics Positive uniQure Positive Which has more volatility and risk, CKPT or QURE? Checkpoint Therapeutics has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500. Comparatively, uniQure has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500. SummaryuniQure beats Checkpoint Therapeutics on 10 of the 18 factors compared between the two stocks. Remove Ads Get Checkpoint Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CKPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CKPT vs. The Competition Export to ExcelMetricCheckpoint TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$196.80M$6.92B$5.65B$8.06BDividend YieldN/A2.72%4.57%4.01%P/E Ratio-2.197.2023.1419.03Price / Sales4,187.17226.01385.7893.17Price / CashN/A65.6738.1634.64Price / Book-8.576.476.934.33Net Income-$51.85M$141.90M$3.20B$247.06M7 Day Performance-0.98%-3.20%-2.30%-0.37%1 Month Performance40.91%-5.64%2.86%-3.85%1 Year Performance96.59%-7.47%10.66%1.27% Checkpoint Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CKPTCheckpoint Therapeutics2.3401 of 5 stars$4.03-0.7%$4.33+7.5%+97.5%$196.80M$47,000.00-2.1910Short Interest ↓QUREuniQure2.6975 of 5 stars$14.64+6.9%$38.89+165.6%+142.7%$791.42M$27.12M-2.95500ABCLAbCellera Biologics2.4747 of 5 stars$2.58+5.5%$7.00+171.8%-47.4%$767.32M$28.83M-4.22500Positive NewsCMRXChimerix3.5537 of 5 stars$8.51+0.1%$8.53+0.3%+741.6%$764.91M$159,000.00-9.0590Earnings ReportShort Interest ↓PRAXPraxis Precision Medicines2.5431 of 5 stars$37.83+1.9%$123.80+227.3%-34.4%$762.81M$8.55M-3.67110Positive NewsLENZLENZ Therapeutics1.7628 of 5 stars$27.28+3.0%$41.67+52.7%+21.6%$750.23MN/A-5.72110BCAXBicara TherapeuticsN/A$13.60+2.7%$36.50+168.4%N/A$735.70MN/A0.0032Earnings ReportUpcoming EarningsAnalyst ForecastNews CoverageCRONCronos Group1.9068 of 5 stars$1.88+4.7%$3.00+60.0%-32.2%$717.25M$117.62M-14.42450PRTAProthena3.3429 of 5 stars$13.38+3.1%$55.00+311.2%-48.3%$714.50M$135.16M-5.77130Analyst RevisionNews CoveragePositive NewsAVBPArriVent BioPharma1.4346 of 5 stars$20.12+3.1%$39.00+93.8%+3.2%$684.40MN/A-7.8340ORGOOrganogenesis3.5813 of 5 stars$5.39+10.4%$5.50+2.1%+69.2%$681.70M$482.04M-89.58950 Remove Ads Related Companies and Tools Related Companies uniQure Competitors AbCellera Biologics Competitors Chimerix Competitors Praxis Precision Medicines Competitors LENZ Therapeutics Competitors Bicara Therapeutics Competitors Cronos Group Competitors Prothena Competitors ArriVent BioPharma Competitors Organogenesis Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CKPT) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Checkpoint Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Checkpoint Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CKPT Stock Free CKPT Stock Alerts